Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors.

M A Grotzer1, A J Janss, K Fung

  • 1Division of Oncology, Department of Pathology, The Children's Hospital of Philadelphia, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|March 1, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.

Neurology·2011
Same author

Inhaled nitric oxide in premature infants: effect on tracheal aspirate and plasma nitric oxide metabolites.

Journal of perinatology : official journal of the California Perinatal Association·2009
Same author

Visual assessment of jaundice in term and late preterm infants.

Archives of disease in childhood. Fetal and neonatal edition·2009
Same author

Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.

Oncogene·2007
Same author

BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma.

Oncogene·2006
Same author

Survival and complications in thalassemia.

Annals of the New York Academy of Sciences·2005

High TrkC mRNA expression in primitive neuroectodermal tumors (PNET) indicates a better prognosis. This finding can help tailor treatment intensity for pediatric PNET patients, including medulloblastoma.

Area of Science:

  • Pediatric Oncology
  • Molecular Diagnostics
  • Cancer Biomarkers

Background:

  • Childhood primitive neuroectodermal tumors (PNET), including medulloblastoma, represent a significant challenge in pediatric oncology.
  • Accurate prognostic factors are crucial for stratifying patients and optimizing treatment intensity.

Purpose of the Study:

  • To identify biologic prognostic factors in pediatric PNETs that predict favorable outcomes.
  • To determine if TrkC mRNA expression levels can identify patients with a good prognosis, potentially allowing for reduced treatment intensity.

Main Methods:

  • In situ hybridization was used to quantify TrkC mRNA expression in tumor samples from 87 pediatric PNET patients.
  • Univariate and multivariate Cox regression analyses were employed to compare TrkC mRNA levels with clinical and laboratory variables.

Related Experiment Videos

Main Results:

  • High TrkC mRNA expression was significantly associated with a higher 5-year survival rate (89%) compared to low expression (46%).
  • TrkC mRNA expression emerged as the most potent predictor of outcome in univariate analysis (HR, 4.81; P <.00005), outperforming established clinical factors.
  • This strong predictive value remained significant in multivariate analysis.

Conclusions:

  • Elevated TrkC mRNA expression is a powerful, independent predictor of favorable outcomes in pediatric PNET.
  • Measuring TrkC mRNA levels can assist in treatment planning for PNET patients.
  • Prospective incorporation of TrkC mRNA assessment into PNET clinical trials is recommended.